Fig. 2.

Ferritin (ng / ml) for all patients with paroxysmal nocturnal haemoglobinuria (PNH) and the four subgroups due to RBC requirement before and at the last follow-up during eculizumab therapy. group 1: no RBC requirement before and during eculizumab therapy; group 2: RBC requirement starting during eculizumab therapy; group 3: RBC transfusion dependency before and ongoing during eculizumab; group 4: RBC transfusion dependency before eculizumab therapy and no further RBC requirement during eculizumab therapy. The solid lines show pts with classical PNH; the dashed lines PNH in the context of another bone marrow disorder.